Optometry

The cost of glaucoma medications is affecting patient compliance with their treatment regimens.

The author analyzes the plight that student loans present in today's society.

A sterile cornea allograft has many advantages that make it a useful alternative to traditional eye bank corneas and other allograft material for a variety of graft procedures where viable endothelium is not needed.

The latest addition to the antihistamine arsenal is alcaftadine ophthalmic solution 0.25%, a new chemical entity developed as an ocular anti-allergic agent.

A novel compound may be able to bring vision to previously blind retinas by switching on remaining ganglion cells in the inner retina.

Improved quality of life for patients with allergic conjunctivitis is the name of the game for Stephen V. Scoper, MD, who uses olopatadine hydrochloride ophthalmic solution 0.2% to treat this patient population because of the increased compliance that the drug affords with its once-daily dosing requirement.

Historically, surgeons performed phacoemulsification with a straight-tip handpiece.

Want to jazz up your office and make a little extra profit at the same time? Read on.

If accessories are not part of your sales strategy, it's time to revisit that decision and explore the myths and realities of this category.

Results from a series of bench studies conducted under strictly controlled conditions consistently indicate that torsional phacoemulsification generates less heat at the incision site than longitudinal phaco.

Some patients who have had previous wavefront-optimized laser vision correction present with quality-of-vision complaints, such as halo and glare, despite having 20/20 visual acuity.

A study evaluating outcomes in eyes undergoing LASIK for >-4 D of myopia reaffirms the established efficacy, safety and predictability of treatments performed with the wavefront-optimized, wavefront-guided and topography-guided ablation profiles of an excimer laser.

Throughout the eye department at Duke, faculty, residents, fellows and scientists work to further the understanding of eye disease and discover potential treatments.

Patients who have undergone cataract surgery with the +3-D add version of the apodized diffractive aspheric multifocal IOL implanted bilaterally demonstrate a significant postoperative improvement in perceived driving ability.

Providing appropriate amount of care to each patient is important.

A dexamethasone intravitreal implant is a notable new therapeutic option for eyes with macular edema secondary to branch retinal vein occlusion or central retinal vein occlusion and may reduce the risk of vision loss as well as improve both the speed and incidence of visual improvement, according to one expert.

A new combined vitrectomy and phacoemulsification system was created to provide advanced technology for vitreoretinal and cataract procedures in a single, compact platform.

Analyses of data collected through 24 months of follow-up in a phase II, prospective, multicenter clinical trial support the conclusion that vascular endothelial growth factor blockade with ranibizumab is beneficial for the treatment of diabetic macular edema.

Primary readout results from 24 months of follow-up in the pivotal phase III fluocinolone acetonide in diabetic macular edema studies demonstrate that a novel investigational corticosteroid-releasing intravitreal insert provides rapid and sustained improvement in visual acuity and macular swelling with an acceptable safety profile.

Despite having a variety of imaging and treatment technologies available for retinal disease management, each technology has inherent properties that define its limitations. Integration of combinations of these technologies promises to be the best remedy for these individual shortcomings and may help achieve optimal outcomes.

Phase II study data indicate that pegaptanib sodium injection is an effective and safe treatment for diabetic macular edema.

Epimacular brachytherapy seems to be a safe and effective approach for treating neovascular age-related macular degeneration based on the 36-month results of the NVI-III pilot study, according to one expert.

ISTA Pharmaceuticals announced Oct. 16 that it had received FDA approval to market bromfenac ophthalmic solution 0.09% as a once-daily treatment for inflammation and reduction of ocular pain in patients who had undergone cataract surgery.

Port-based flow limiting is safer for the patient during vitreoretinal surgery because it is so instantaneous, does not occur at the console, and helps prevent retinal breaks.

Results of a recent clinical sutdy provide promising evidence of the value of ultra-widefield fundus autofluorescence imaging in the evaluation of age-related macular degeneration.